Dongyao Pharmaceutical-B (01875.HK)'s revenue in the first three quarters increased 77% to 542 million yuan, and sales of self-developed products increased significantly

Gelonghui Finance · Nov 10, 2023 04:38

Gelonghui November 10th 丨Dongyao Pharmaceutical-B (01875.HK) announced that during the nine-month period ending September 30, 2023, the Group's revenue increased 77% year-on-year to RMB 542 million, mainly due to the sharp increase in sales of self-developed products and the rapid increase in CDMO/CMO business.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

东曜药业-B(01875.HK)前三季度营收增77%至5.42亿元 自研产品销量大幅度增加

Dongyao Pharmaceutical-B (01875.HK)'s revenue in the first three quarters increased 77% to 542 million yuan, and sales of self-developed products increased significantly

Risk Disclaimer

Statement

东曜药业-B(01875.HK)前三季度营收增77%至5.42亿元自研产品销量大幅度增加